Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 12/20 | 0.84 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.84 |
| ▸ | DAGLB | Q8NCG7 | 11/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13192827 | 0.92 | DAGLA (1.00) | DAGLAABHD6DAGLB | |
| SCHEMBL15426552 | 0.91 | DAGLA (0.86) | DAGLAABHD6DAGLB | |
| SCHEMBL15427259 | 0.89 | DAGLA (0.84) | DAGLAABHD6DAGLB | |
| SCHEMBL30095999 | 0.89 | DAGLA (0.84) | DAGLAABHD6DAGLB | |
| SCHEMBL13192446 | 0.88 | DAGLA (0.81) | DAGLAABHD6DAGLB | |
| SCHEMBL20575923 | 0.87 | DAGLA (1.00) | DAGLAABHD6DAGLB | |
| SCHEMBL20575830 | 0.86 | DAGLA (1.00) | DAGLAABHD6DAGLB | |
| SCHEMBL18936598 | 0.86 | DAGLA (0.92) | DAGLAABHD6DAGLB | |
| SCHEMBL15426530 | 0.85 | DAGLA (0.80) | DAGLAABHD6DAGLB | |
| SCHEMBL13192823 | 0.85 | DAGLA (0.86) | DAGLAABHD6DAGLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108930-B2 | N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140018318-A1 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | THE SCIPPS RESEARCH INSTITUTE (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018318-A1 | N1- and N2-CARBAMOYL-1,2,3-TRIAZOLE SERINE HYDROLASE INHIBITORS AND METHODS | PRSS1, PRSS3, CES1 | DAGLA 2511/4885ABHD6 1961/4885DAGLB 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.